Table 1.
Baseline characteristics of patients with HS or AD
| HS (n = 13) | AD (n = 8) | |
|---|---|---|
| Sex, n (%) | ||
| Female | 10 (76.9) | 3 (37.5) |
| Male | 3 (23.1) | 5 (62.5) |
| Age (years) | ||
| Median (range) | 40.0 (21 – 53) | 31.0 (23 – 55) |
| Disease severity at baseline, n (%) | HS-PGA | vIGA-AD |
| Mild | 0 | 1 (12.5) |
| Moderate | 10 (76.9) | 5 (62.5) |
| Severe | 1 (7.7) | 2 (25.0) |
| Very severe | 2 (15.4) | 0 |
| Extent of disease at baseline mean (min, max) | ||
| AN count | 8.4 (5, 18) | - |
| Fistula count | 3.8 (0, 15) | - |
| Pain NRS (worst over past 24 h) | 5.5 (0, 10) | - |
| Pain NRS (worst over past week) | 6.8 (3, 10) | - |
| Pruritus NRS (worst over 24 h) | 3.3 (0, 9) | 7.1 (2, 10) |
| Pruritus NRS (worst over past week) | 5.2 (0, 10) | 7.6 (4, 10) |
| EASI score | - | 17.6 (4.4, 52.3) |
| Patients with any prior therapy, n (%) | ||
| Antibiotics/antibacterials | 5 (38.5)a | 1 (12.5) |
| Corticosteroids | 0 | 7 (87.5) |
| Adalimumab | 3 (23.1) | 0 |
| Other biologics | 1 (7.7) | 0 |
a Includes two topical medications that are not coded as antibiotics (clindamycin and chlorhexidine).
vIGA-AD, validated Investigator Global Assessment for atopic dermatitis.